AMS Health Sciences, Inc. Announces Ephedra Lawsuit Settlement

AMS Health Sciences, Inc (AMEX:AMM) announced today the
settlement of Randal Potter et al v. Advantage Marketing Systems,
Inc., the final lawsuit pending against the Company involving its
products containing ephedra. In Potter, the plaintiff alleged that the
ingestion of ephedra included in the Company's AM-300 product resulted
in the death of Pamela Sue Potter. The exact settlement terms are
confidential.
   "This is a tremendous relief for the Company and its
stockholders," said Dr. Jerry W. Grizzle, President and CEO of AMS.
"We have worked diligently with all parties involved to bring this to
an equitable and satisfactory closing. This settlement releases the
Company from all liabilities, current or future, related to the claims
alleged in the original lawsuit." This settlement resolves the last
piece of litigation dealing with the sale of AM-300, an ephedra-based
product. The Food and Drug Administration (FDA) banned the sale of
ephedra in April 2004. In compliance with the FDA ruling, the Company
terminated all sales of AM-300. The Company is not aware of any other
claims that might result in future litigation regarding the ingestion
of ephedra through the Company's products.
   AMS Health Sciences, Inc., sells more than 60 natural nutritional
supplements, weight management products, and natural skincare products
through independent distributors across the United States and Canada.
More information about the Company is available at
http://www.amsonline.com.